Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world poor prognostic impact of del(1p32) in newly diagnosed multiple myeloma among Asian populations

View Full Paper
Ask AI
Bookmark
Share

Authors

WTWenjiao TangLZLi Zhang

Discussion

Loading...

Member takes

Overview

Research reveals del(1p32) worsens progression-free survival in newly diagnosed multiple myeloma patients, suggesting a need for tailored therapies.

Key Points

  • Del(1p32) was associated with significantly shorter progression-free survival, with a median of 21.5 months compared to 31.7 months in non-carriers.
  • The study evaluated 279 patients in a retrospective analysis, highlighting the adverse impact on outcomes among those with the del(1p32) deletion.
  • Cox regression analyses indicated that higher stage R-ISS disease and elevated serum LDH levels correlated with del(1p32) status among patients.
  • The findings underscore the need for new risk stratification models considering del(1p32) to improve outcomes for affected Asian patients.

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1d5https://doi.org/10.1182/blood-2025-7514
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone2025 · 3 citations
  2. 2Prognostic significance of 1q21 gain/amplification and co-existing cytogenetic abnormalities in Chinese patients with newly diagnosed multiple myeloma2025
  3. 3Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation2026
  4. 4Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.2025
  5. 5Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma2025 · 1 citations